View ValuationAFYREN SAS 향후 성장Future 기준 점검 0/6AFYREN SAS (는) 각각 연간 33.7% 및 0.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 53.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -12.9% 로 예상됩니다.핵심 정보33.7%이익 성장률53.73%EPS 성장률Chemicals 이익 성장11.1%매출 성장률0.6%향후 자기자본이익률-12.90%애널리스트 커버리지Low마지막 업데이트01 Apr 2026최근 향후 성장 업데이트공시 • Jan 15AFYREN Provides Revenue Guidance for the Full Year 2026AFYREN provides revenue guidance for the full year 2026. For the period, The company expects revenue growth to accelerate.Major Estimate Revision • Nov 27Consensus EPS estimates upgraded to €0.35 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -€0.495 to -€0.355 per share. Revenue forecast unchanged from €3.20m at last update. Chemicals industry in France expected to see average net income growth of 18% next year. Consensus price target down from €5.20 to €5.00. Share price rose 8.1% to €2.41 over the past week.공시 • Sep 12Afyren Sas Provides Revenue Guidance for 2025AFYREN SAS provided revenue guidance for 2025. For the period, the company expects production revenue in the low single-digit million euros range.Major Estimate Revision • Jul 18Consensus revenue estimates increase by 867%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €3.00m to €29.0m. EPS estimate fell from -€0.33 to -€0.61 per share. Chemicals industry in France expected to see average net income growth of 12% next year. Consensus price target of €5.00 unchanged from last update. Share price fell 2.2% to €2.26 over the past week.Major Estimate Revision • Jun 18Consensus revenue estimates decrease by 32%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €4.40m to €3.00m. EPS estimate unchanged from -€0.33 per share at last update. Chemicals industry in France expected to see average net income growth of 13% next year. Consensus price target of €5.00 unchanged from last update. Share price rose 6.8% to €2.99 over the past week.Price Target Changed • Mar 25Price target increased by 10% to €5.00Up from €4.53, the current price target is an average from 2 analysts. New target price is 212% above last closing price of €1.61. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.57 next year compared to a net loss per share of €0.37 last year.모든 업데이트 보기Recent updatesNew Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€7.1m net loss in 2 years). Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (€2.3m revenue, or US$2.7m). Market cap is less than US$100m (€64.5m market cap, or US$75.7m).공시 • Apr 26Afyren Receives EUR 3 Million Grant from Grand Est Region Through European Just Transition FundAfyren received a EUR 3 million grant from the Grand Est Region through the European Just Transition Fund. The European Union has established the Just Transition Fund in the most strategic regions and sectors. In order to meet the actual needs of local territories, Europe has entrusted management of these funds to selected regions. In this context, Afyren was selected by the Grand Est Region to benefit from this support, which will contribute to financing performance investments at the Afyren Neoxy plant, now 100% owned by Afyren. This grant illustrates the development potential of the biorefinery and, more broadly, the creation of value, jobs, and sustainable skills driven by the company, one of the few greentech players to have successfully crossed the threshold of industrial-scale production and commercialization. It is also in recognition of this level of maturity, and thanks to the achievement of the defined milestones, that Afyren received the final instalment of EUR 2.2 million in March 2026 under Bpifrance’s “France Relance” grant, aimed at supporting strategic investments in critical sectors.공시 • Apr 02AFYREN SAS, Annual General Meeting, Jun 16, 2026AFYREN SAS, Annual General Meeting, Jun 16, 2026. Location: lyon FranceReported Earnings • Apr 02Full year 2025 earnings releasedFull year 2025 results: Net income: (up €9.75m from FY 2024).New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 28% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 28% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€7.1m net loss in 2 years). Revenue is less than US$5m (€2.7m revenue, or US$3.1m). Market cap is less than US$100m (€68.0m market cap, or US$78.3m).공시 • Apr 01AFYREN SAS (ENXTPA:ALAFY) acquired remaining 49% stake in Afyren Neoxy from Fonds Sociétés de Projets Industriels, FPCI funds managed by Bpifrance Investissement SAS for €11.3 million.AFYREN SAS (ENXTPA:ALAFY) acquired remaining 49% stake in Afyren Neoxy from Fonds Sociétés de Projets Industriels, FPCI funds managed by Bpifrance Investissement SAS for €11.3 million on March 31, 2026. As a result of the transaction, AFYREN now holds 100% of the subsidiary AFYREN SAS (ENXTPA:ALAFY) completed the acquisition of remaining 49% stake in Afyren Neoxy from Fonds Sociétés de Projets Industriels, FPCI funds managed by Bpifrance Investissement SAS on March 31, 2026.New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€10.0m net loss in 2 years). Revenue is less than US$5m (€2.7m revenue, or US$3.1m). Market cap is less than US$100m (€71.5m market cap, or US$82.4m).공시 • Feb 27AFYREN SAS has completed a Follow-on Equity Offering in the amount of €7 million.AFYREN SAS has completed a Follow-on Equity Offering in the amount of €7 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,745,098 Price\Range: €2.55공시 • Jan 15AFYREN Provides Revenue Guidance for the Full Year 2026AFYREN provides revenue guidance for the full year 2026. For the period, The company expects revenue growth to accelerate.공시 • Dec 19+ 1 more updateAFYREN SAS to Report Fiscal Year 2025 Results on Mar 31, 2026AFYREN SAS announced that they will report fiscal year 2025 results After-Market on Mar 31, 2026Major Estimate Revision • Nov 27Consensus EPS estimates upgraded to €0.35 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -€0.495 to -€0.355 per share. Revenue forecast unchanged from €3.20m at last update. Chemicals industry in France expected to see average net income growth of 18% next year. Consensus price target down from €5.20 to €5.00. Share price rose 8.1% to €2.41 over the past week.공시 • Nov 26AFYREN SAS announced that it has received €22.999999 million in funding from Kemin Industries, Bpifrance Investissement SASAFYREN SAS announced a private placement of 95,83,333 common shares at a price of €2.40 per share for gross proceeds of €22,999,999.20 on November 25, 2025. The transaction included participation from new investor Kemin Industries, and returning investor Bpifrance Investissement SAS.Reported Earnings • Sep 12First half 2025 earnings released: €0.27 loss per share (vs €0.20 loss in 1H 2024)First half 2025 results: €0.27 loss per share (further deteriorated from €0.20 loss in 1H 2024). Net loss: €6.92m (loss widened 30% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.공시 • Sep 12Afyren Sas Provides Revenue Guidance for 2025AFYREN SAS provided revenue guidance for 2025. For the period, the company expects production revenue in the low single-digit million euros range.Major Estimate Revision • Jul 18Consensus revenue estimates increase by 867%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €3.00m to €29.0m. EPS estimate fell from -€0.33 to -€0.61 per share. Chemicals industry in France expected to see average net income growth of 12% next year. Consensus price target of €5.00 unchanged from last update. Share price fell 2.2% to €2.26 over the past week.New Risk • Jul 18New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€8.5m net loss in 3 years). Revenue is less than US$5m (€2.9m revenue, or US$3.3m). Market cap is less than US$100m (€59.5m market cap, or US$69.3m).New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.8m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€8.3m net loss in 3 years). Revenue is less than US$5m (€2.9m revenue, or US$3.4m). Market cap is less than US$100m (€70.5m market cap, or US$83.3m).Major Estimate Revision • Jun 18Consensus revenue estimates decrease by 32%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €4.40m to €3.00m. EPS estimate unchanged from -€0.33 per share at last update. Chemicals industry in France expected to see average net income growth of 13% next year. Consensus price target of €5.00 unchanged from last update. Share price rose 6.8% to €2.99 over the past week.공시 • Apr 10AFYREN SAS Appoints Laurent Pou as Industrial DirectorAFYREN SAS announces the strengthening of its Executive Committee with the appointment of Laurent Pou as Industrial Director, a strategic position as the Group’s first biorefinery, AFYREN NEOXY, enters the final phase of industrial start-up. A chemical engineering graduate of ENSIC Nancy and University College London, Laurent Pou has extensive experience with international companies such as Tereos and ExxonMobil. His 25 years’ experience in the chemicals and agrochemicals industry and his strong expertise in industrial plant start-ups, operations management and the industrial and economic optimisation of production assets are key strengths for the forthcoming continuous operation phase of AFYREN NEOXY and the ramp-up period that will follow. This appointment follows on from the strengthening of the Executive Committee around industrial skills: Ursula Feulner, Director of Industrial Projects since early 2022, joined AFYREN’s Executive Committee in 2024.Reported Earnings • Mar 27Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: €0.37 loss per share (in line with FY 2023). Net loss: €9.75m (loss widened 1.8% from FY 2023). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 35%. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings.Price Target Changed • Mar 25Price target increased by 10% to €5.00Up from €4.53, the current price target is an average from 2 analysts. New target price is 212% above last closing price of €1.61. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.57 next year compared to a net loss per share of €0.37 last year.New Risk • Feb 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€7.8m net loss in 3 years). Revenue is less than US$5m (€2.8m revenue, or US$2.9m). Market cap is less than US$100m (€57.4m market cap, or US$60.3m).공시 • Jan 17AFYREN SAS, Annual General Meeting, Jun 17, 2025AFYREN SAS, Annual General Meeting, Jun 17, 2025.공시 • Jan 15+ 1 more updateAFYREN SAS to Report First Half, 2025 Results on Sep 25, 2025AFYREN SAS announced that they will report first half, 2025 results on Sep 25, 2025Reported Earnings • Oct 04First half 2024 earnings released: €0.20 loss per share (vs €0.20 loss in 1H 2023)First half 2024 results: €0.20 loss per share (further deteriorated from €0.20 loss in 1H 2023). Net loss: €5.32m (loss widened 3.9% from 1H 2023). Revenue is forecast to grow 99% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 28% per year whereas the company’s share price has fallen by 29% per year.공시 • Oct 01AFYREN Provides Production Guidance for the Year 2024AFYREN provided production guidance for the year 2024. The company aims for: three production units with an installed capacity of around 70,000 tons of acids in 2028, including at least two in continuous production (including the existing AFYREN NEOXY plant). These three units will also produce a high added-value fertilizer to ensure the circularity of the model; With all three units running at full capacity, the company aims for: cumulated production revenue of more than €150 million.공시 • Jul 09AFYREN's Fermentation Lab Reaches 2-Million-Hour Mark as It Identifies New Raw Materials to Fuel Industrial ExpansionAFYREN announced that it confirms its innovative approach and identifies the biomass families that will underpin its industrial expansion. The announcement comes as the company hit the milestone of 2 million hours of fermentation in its R&D lab. A unique technology based on biomimicry: Based on a decade of research in chemistry and biology and protected worldwide by 10 patent families, the AFYNERIE® process converts a wide range of organic raw materials into bio-based molecules using natural, non-genetically modified micro-organisms. Inspired by living organisms and entirely biomimetic, the process reproduces on an industrial scale the fermentation that has been around for millions of years in natural ecosystems and on which, for example, the mechanization process, used for energy production, is based. AFYREN's expertise lies in controlling the transformation of the bio-based raw material to promote the production of carboxylic acids. The acids are extracted then processed through separation and purification stages to obtain products that meet industry specifications and current regulations. This quality is at the heart of the 'drop-in' approach, which enables direct replacement of petro-based molecules by bio-based molecules in its clients' existing production process. The end products are commonly found for example in food products or cosmetics, opening up markets that go well beyond those offered by mechanization. 60 biomass families identified and available to support AFYREN's international development and secure its supply of raw materials. On the strength of its successful experience in valorizing by-products from the sugar industry at the AFYREN NEOXY plant in France, AFYREN is continuing its work to identify new sources of raw materials. Since the company was founded, AFYREN's R&D teams, made up of chemists and biologists, have carried out tests on more than 300 potential raw materials made available by the players and partners in the agri-food and farming industries around the world. These tests have enabled AFYREN to qualify 60 families of biomass (agricultural by-products, by-products of the food industry, etc.) that can be transformed into 100% bio-based molecules on an industrial scale. The recent partnership signed with SUEZ even paves the way for the recovery of household organic waste. This work proves that a wide range of organic raw materials can be upcycled in this way, even though they were originally considered to be of little use. This work, carried out on samples from all over the world, is crucial for international development at AFYREN, whose strategy is based on short supply chains with regional sourcing. Innovation fully dedicated to the development of new circular value chains: AFYREN's innovation approach is based on three strategic pillars. Each project must aim to improve processes, support international expansion by exploring new biomass families, or contribute to the development of innovative products and derivatives. For this work, partnerships are often the preferred option. Within this framework, R&D is working in particular on perfecting processes to optimize yields and make AFYREN's industrial solution more competitive. Working closely with the business development team, the R&D teams are also trying to expand the company’s portfolio of acids and their derivatives. The acids produced by AFYREN are platform molecules which, thanks to additional green chemistry steps (esterification, hydrogenation, etc.) can be transformed into derivatives and new products. AFYREN's innovation portfolio currently comprises around ten projects aimed at developing partnerships for new products and circular value chains. It follows an eco-design rationale, incorporating corporate social responsibility (CSR) performance criteria such as carbon footprint, energy mix or the nature of raw materials and their transport.New Risk • May 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 9.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings are forecast to decline by an average of 9.9% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€11m net loss in 3 years). Revenue is less than US$5m (€3.4m revenue, or US$3.6m). Market cap is less than US$100m (€70.5m market cap, or US$75.9m).Major Estimate Revision • Apr 09Consensus revenue estimates decrease by 14%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €4.07m to €3.50m. EPS estimate increased from -€0.723 to -€0.44 per share. Chemicals industry in France expected to see average net income growth of 20% next year. Consensus price target down from €6.30 to €5.75. Share price rose 2.9% to €1.96 over the past week.Reported Earnings • Apr 03Full year 2023 earnings released: €0.37 loss per share (vs €0.36 loss in FY 2022)Full year 2023 results: €0.37 loss per share (further deteriorated from €0.36 loss in FY 2022). Net loss: €9.59m (loss widened 4.2% from FY 2022). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in France.New Risk • Jan 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 41% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€5.6m net loss in 3 years). Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (41% increase in shares outstanding). Revenue is less than US$5m (€3.6m revenue, or US$4.0m). Market cap is less than US$100m (€73.4m market cap, or US$79.8m).공시 • Jan 09+ 2 more updatesAFYREN SAS to Report Fiscal Year 2023 Results on Apr 02, 2024AFYREN SAS announced that they will report fiscal year 2023 results on Apr 02, 2024New Risk • Dec 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€4.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.7m free cash flow). Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Revenue is less than US$5m (€3.6m revenue, or US$4.0m). Market cap is less than US$100m (€53.3m market cap, or US$58.1m).Price Target Changed • Dec 15Price target decreased by 18% to €7.17Down from €8.77, the current price target is an average from 3 analysts. New target price is 248% above last closing price of €2.06. Stock is down 67% over the past year. The company is forecast to post a net loss per share of €0.43 next year compared to a net loss per share of €0.36 last year.New Risk • Oct 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €94.2m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Revenue is less than US$5m (€3.6m revenue, or US$3.9m). Market cap is less than US$100m (€94.2m market cap, or US$99.5m).Major Estimate Revision • Sep 26Consensus revenue estimates increase by 14%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from €3.43m to €3.90m. Forecast losses expected to reduce from -€0.53 to -€0.435 per share. Chemicals industry in France expected to see average net income growth of 1.4% next year. Consensus price target broadly unchanged at €8.60. Share price fell 5.2% to €4.74 over the past week.Reported Earnings • Sep 20First half 2023 earnings released: €0.20 loss per share (vs €0.16 loss in 1H 2022)First half 2023 results: €0.20 loss per share (further deteriorated from €0.16 loss in 1H 2022). Net loss: €5.12m (loss widened 23% from 1H 2022). Revenue is forecast to grow 87% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in France.Price Target Changed • Sep 20Price target decreased by 7.5% to €8.60Down from €9.30, the current price target is an average from 3 analysts. New target price is 74% above last closing price of €4.93. Stock is down 30% over the past year. The company is forecast to post a net loss per share of €0.43 next year compared to a net loss per share of €0.36 last year.New Risk • Jul 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€3.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.8m free cash flow). Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€16m net loss in 3 years). Share price has been volatile over the past 3 months (6.6% average weekly change). Revenue is less than US$5m (€3.5m revenue, or US$3.8m).Major Estimate Revision • Mar 29Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€0.363 to -€0.417 per share. Revenue forecast of €3.80m unchanged since last update. Chemicals industry in France expected to see average net income decline 0.5% next year. Consensus price target down from €9.30 to €8.77. Share price fell 3.7% to €4.71 over the past week.Reported Earnings • Mar 22Third quarter 2022 earnings released: €0.099 loss per share (vs €0.048 loss in 3Q 2021)Third quarter 2022 results: €0.099 loss per share (further deteriorated from €0.048 loss in 3Q 2021). Net loss: €2.52m (loss widened 144% from 3Q 2021). Revenue is forecast to grow 57% p.a. on average during the next 4 years, compared to a 4.0% growth forecast for the Chemicals industry in France.공시 • Jan 10AFYREN Announces Appointment to Its Management TeamAFYREN announced the appointment of three new members to its management team as well as new hires to support its development in France and abroad and to step up its R&D activities. Three strategic appointments Ursula Feulner - Director for Industrial Project Management:- Ursula joins AFYREN's operations team and will lead the upstream phases of industrial projects, including the construction of new plants. AFYREN benefits from her long experience with the SUEZ Group, where she had various roles closely related to the management of industrial projects in Europe, North America, the Middle East and Asia, and worked in risk management for a number of strategic projects. Lea Bassegoda - Human Resources Director:- Lea joins AFYREN to supervise the expansion of its teams. After several years in France and the United States with LVMH and then Danone, she will use her skills and solid experience to build a global Human Resources policy within the group and to structure the organization in line with the company's culture and strong values. Christophe Dardel - Strategic Partnerships Director:- Christophe has come onboard to identify and lay the groundwork for future international factory projects and related strategic partnerships. He has long and solid international experience acquired at several companies, and in particular with Royal DSM for more than 15 years. As a former member of the Executive Committee, Christophe was in charge of the development of the DSM Dyneema unit, which experienced strong organic growth through the establishment of several factories and key partnerships around the world.공시 • Dec 14+ 2 more updatesAFYREN SAS to Report First Half, 2023 Results on Oct 02, 2023AFYREN SAS announced that they will report first half, 2023 results on Oct 02, 2023Price Target Changed • Nov 16Price target decreased to €9.30Down from €10.70, the current price target is an average from 3 analysts. New target price is 89% above last closing price of €4.93. Stock is down 46% over the past year.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Patrizia Marraghini was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 28First half 2022 earnings released: EPS: €0 (vs €0.44 loss in 1H 2021)First half 2022 results: EPS: €0. Net loss: €4.16m (loss widened 170% from 1H 2021). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Chemicals industry in France.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Chairman of the Board Stefan Borgas was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Chairman of the Board Stefan Borgas was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측ENXTPA:ALAFY - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20272-7-28-6112/31/20262-11-24-4112/31/20252-14-6-6N/A9/30/20252-13-5-5N/A6/30/20253-11-5-5N/A3/31/20253-11-6-5N/A12/31/20243-10-6-6N/A9/30/20243-10-6-6N/A6/30/20243-10-6-6N/A3/31/20243-10-6-6N/A12/31/20233-10-6-5N/A9/30/20234-10-5-5N/A6/30/20234-10-5-4N/A3/31/20234-10-4-4N/A12/31/20223-9-4-3N/A9/30/20223-8-3-3N/A6/30/20223-6-3-3N/A3/31/20223-5-3-3N/A12/31/20213-4-3-3N/A9/30/20213-3-3-3N/A6/30/20213-3-3-2N/A3/31/20214-2-2-1N/A12/31/20204-2-10N/A12/31/20192-2-1-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: ALAFY 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: ALAFY 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: ALAFY 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: ALAFY 의 수익(연간 0.6%)이 French 시장(연간 5.6%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: ALAFY 의 수익(연간 0.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: ALAFY는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 19:18종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AFYREN SAS는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Christophe-Raphael GanetODDO BHF Corporate & MarketsJeremy GarnierODDO BHF Corporate & MarketsHana MaalejODDO BHF Corporate & Markets1명의 분석가 더 보기
공시 • Jan 15AFYREN Provides Revenue Guidance for the Full Year 2026AFYREN provides revenue guidance for the full year 2026. For the period, The company expects revenue growth to accelerate.
Major Estimate Revision • Nov 27Consensus EPS estimates upgraded to €0.35 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -€0.495 to -€0.355 per share. Revenue forecast unchanged from €3.20m at last update. Chemicals industry in France expected to see average net income growth of 18% next year. Consensus price target down from €5.20 to €5.00. Share price rose 8.1% to €2.41 over the past week.
공시 • Sep 12Afyren Sas Provides Revenue Guidance for 2025AFYREN SAS provided revenue guidance for 2025. For the period, the company expects production revenue in the low single-digit million euros range.
Major Estimate Revision • Jul 18Consensus revenue estimates increase by 867%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €3.00m to €29.0m. EPS estimate fell from -€0.33 to -€0.61 per share. Chemicals industry in France expected to see average net income growth of 12% next year. Consensus price target of €5.00 unchanged from last update. Share price fell 2.2% to €2.26 over the past week.
Major Estimate Revision • Jun 18Consensus revenue estimates decrease by 32%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €4.40m to €3.00m. EPS estimate unchanged from -€0.33 per share at last update. Chemicals industry in France expected to see average net income growth of 13% next year. Consensus price target of €5.00 unchanged from last update. Share price rose 6.8% to €2.99 over the past week.
Price Target Changed • Mar 25Price target increased by 10% to €5.00Up from €4.53, the current price target is an average from 2 analysts. New target price is 212% above last closing price of €1.61. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.57 next year compared to a net loss per share of €0.37 last year.
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€7.1m net loss in 2 years). Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (€2.3m revenue, or US$2.7m). Market cap is less than US$100m (€64.5m market cap, or US$75.7m).
공시 • Apr 26Afyren Receives EUR 3 Million Grant from Grand Est Region Through European Just Transition FundAfyren received a EUR 3 million grant from the Grand Est Region through the European Just Transition Fund. The European Union has established the Just Transition Fund in the most strategic regions and sectors. In order to meet the actual needs of local territories, Europe has entrusted management of these funds to selected regions. In this context, Afyren was selected by the Grand Est Region to benefit from this support, which will contribute to financing performance investments at the Afyren Neoxy plant, now 100% owned by Afyren. This grant illustrates the development potential of the biorefinery and, more broadly, the creation of value, jobs, and sustainable skills driven by the company, one of the few greentech players to have successfully crossed the threshold of industrial-scale production and commercialization. It is also in recognition of this level of maturity, and thanks to the achievement of the defined milestones, that Afyren received the final instalment of EUR 2.2 million in March 2026 under Bpifrance’s “France Relance” grant, aimed at supporting strategic investments in critical sectors.
공시 • Apr 02AFYREN SAS, Annual General Meeting, Jun 16, 2026AFYREN SAS, Annual General Meeting, Jun 16, 2026. Location: lyon France
Reported Earnings • Apr 02Full year 2025 earnings releasedFull year 2025 results: Net income: (up €9.75m from FY 2024).
New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 28% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 28% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€7.1m net loss in 2 years). Revenue is less than US$5m (€2.7m revenue, or US$3.1m). Market cap is less than US$100m (€68.0m market cap, or US$78.3m).
공시 • Apr 01AFYREN SAS (ENXTPA:ALAFY) acquired remaining 49% stake in Afyren Neoxy from Fonds Sociétés de Projets Industriels, FPCI funds managed by Bpifrance Investissement SAS for €11.3 million.AFYREN SAS (ENXTPA:ALAFY) acquired remaining 49% stake in Afyren Neoxy from Fonds Sociétés de Projets Industriels, FPCI funds managed by Bpifrance Investissement SAS for €11.3 million on March 31, 2026. As a result of the transaction, AFYREN now holds 100% of the subsidiary AFYREN SAS (ENXTPA:ALAFY) completed the acquisition of remaining 49% stake in Afyren Neoxy from Fonds Sociétés de Projets Industriels, FPCI funds managed by Bpifrance Investissement SAS on March 31, 2026.
New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€10.0m net loss in 2 years). Revenue is less than US$5m (€2.7m revenue, or US$3.1m). Market cap is less than US$100m (€71.5m market cap, or US$82.4m).
공시 • Feb 27AFYREN SAS has completed a Follow-on Equity Offering in the amount of €7 million.AFYREN SAS has completed a Follow-on Equity Offering in the amount of €7 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,745,098 Price\Range: €2.55
공시 • Jan 15AFYREN Provides Revenue Guidance for the Full Year 2026AFYREN provides revenue guidance for the full year 2026. For the period, The company expects revenue growth to accelerate.
공시 • Dec 19+ 1 more updateAFYREN SAS to Report Fiscal Year 2025 Results on Mar 31, 2026AFYREN SAS announced that they will report fiscal year 2025 results After-Market on Mar 31, 2026
Major Estimate Revision • Nov 27Consensus EPS estimates upgraded to €0.35 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -€0.495 to -€0.355 per share. Revenue forecast unchanged from €3.20m at last update. Chemicals industry in France expected to see average net income growth of 18% next year. Consensus price target down from €5.20 to €5.00. Share price rose 8.1% to €2.41 over the past week.
공시 • Nov 26AFYREN SAS announced that it has received €22.999999 million in funding from Kemin Industries, Bpifrance Investissement SASAFYREN SAS announced a private placement of 95,83,333 common shares at a price of €2.40 per share for gross proceeds of €22,999,999.20 on November 25, 2025. The transaction included participation from new investor Kemin Industries, and returning investor Bpifrance Investissement SAS.
Reported Earnings • Sep 12First half 2025 earnings released: €0.27 loss per share (vs €0.20 loss in 1H 2024)First half 2025 results: €0.27 loss per share (further deteriorated from €0.20 loss in 1H 2024). Net loss: €6.92m (loss widened 30% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.
공시 • Sep 12Afyren Sas Provides Revenue Guidance for 2025AFYREN SAS provided revenue guidance for 2025. For the period, the company expects production revenue in the low single-digit million euros range.
Major Estimate Revision • Jul 18Consensus revenue estimates increase by 867%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €3.00m to €29.0m. EPS estimate fell from -€0.33 to -€0.61 per share. Chemicals industry in France expected to see average net income growth of 12% next year. Consensus price target of €5.00 unchanged from last update. Share price fell 2.2% to €2.26 over the past week.
New Risk • Jul 18New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€8.5m net loss in 3 years). Revenue is less than US$5m (€2.9m revenue, or US$3.3m). Market cap is less than US$100m (€59.5m market cap, or US$69.3m).
New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.8m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€8.3m net loss in 3 years). Revenue is less than US$5m (€2.9m revenue, or US$3.4m). Market cap is less than US$100m (€70.5m market cap, or US$83.3m).
Major Estimate Revision • Jun 18Consensus revenue estimates decrease by 32%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €4.40m to €3.00m. EPS estimate unchanged from -€0.33 per share at last update. Chemicals industry in France expected to see average net income growth of 13% next year. Consensus price target of €5.00 unchanged from last update. Share price rose 6.8% to €2.99 over the past week.
공시 • Apr 10AFYREN SAS Appoints Laurent Pou as Industrial DirectorAFYREN SAS announces the strengthening of its Executive Committee with the appointment of Laurent Pou as Industrial Director, a strategic position as the Group’s first biorefinery, AFYREN NEOXY, enters the final phase of industrial start-up. A chemical engineering graduate of ENSIC Nancy and University College London, Laurent Pou has extensive experience with international companies such as Tereos and ExxonMobil. His 25 years’ experience in the chemicals and agrochemicals industry and his strong expertise in industrial plant start-ups, operations management and the industrial and economic optimisation of production assets are key strengths for the forthcoming continuous operation phase of AFYREN NEOXY and the ramp-up period that will follow. This appointment follows on from the strengthening of the Executive Committee around industrial skills: Ursula Feulner, Director of Industrial Projects since early 2022, joined AFYREN’s Executive Committee in 2024.
Reported Earnings • Mar 27Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: €0.37 loss per share (in line with FY 2023). Net loss: €9.75m (loss widened 1.8% from FY 2023). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 35%. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings.
Price Target Changed • Mar 25Price target increased by 10% to €5.00Up from €4.53, the current price target is an average from 2 analysts. New target price is 212% above last closing price of €1.61. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.57 next year compared to a net loss per share of €0.37 last year.
New Risk • Feb 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€7.8m net loss in 3 years). Revenue is less than US$5m (€2.8m revenue, or US$2.9m). Market cap is less than US$100m (€57.4m market cap, or US$60.3m).
공시 • Jan 17AFYREN SAS, Annual General Meeting, Jun 17, 2025AFYREN SAS, Annual General Meeting, Jun 17, 2025.
공시 • Jan 15+ 1 more updateAFYREN SAS to Report First Half, 2025 Results on Sep 25, 2025AFYREN SAS announced that they will report first half, 2025 results on Sep 25, 2025
Reported Earnings • Oct 04First half 2024 earnings released: €0.20 loss per share (vs €0.20 loss in 1H 2023)First half 2024 results: €0.20 loss per share (further deteriorated from €0.20 loss in 1H 2023). Net loss: €5.32m (loss widened 3.9% from 1H 2023). Revenue is forecast to grow 99% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has fallen by 28% per year whereas the company’s share price has fallen by 29% per year.
공시 • Oct 01AFYREN Provides Production Guidance for the Year 2024AFYREN provided production guidance for the year 2024. The company aims for: three production units with an installed capacity of around 70,000 tons of acids in 2028, including at least two in continuous production (including the existing AFYREN NEOXY plant). These three units will also produce a high added-value fertilizer to ensure the circularity of the model; With all three units running at full capacity, the company aims for: cumulated production revenue of more than €150 million.
공시 • Jul 09AFYREN's Fermentation Lab Reaches 2-Million-Hour Mark as It Identifies New Raw Materials to Fuel Industrial ExpansionAFYREN announced that it confirms its innovative approach and identifies the biomass families that will underpin its industrial expansion. The announcement comes as the company hit the milestone of 2 million hours of fermentation in its R&D lab. A unique technology based on biomimicry: Based on a decade of research in chemistry and biology and protected worldwide by 10 patent families, the AFYNERIE® process converts a wide range of organic raw materials into bio-based molecules using natural, non-genetically modified micro-organisms. Inspired by living organisms and entirely biomimetic, the process reproduces on an industrial scale the fermentation that has been around for millions of years in natural ecosystems and on which, for example, the mechanization process, used for energy production, is based. AFYREN's expertise lies in controlling the transformation of the bio-based raw material to promote the production of carboxylic acids. The acids are extracted then processed through separation and purification stages to obtain products that meet industry specifications and current regulations. This quality is at the heart of the 'drop-in' approach, which enables direct replacement of petro-based molecules by bio-based molecules in its clients' existing production process. The end products are commonly found for example in food products or cosmetics, opening up markets that go well beyond those offered by mechanization. 60 biomass families identified and available to support AFYREN's international development and secure its supply of raw materials. On the strength of its successful experience in valorizing by-products from the sugar industry at the AFYREN NEOXY plant in France, AFYREN is continuing its work to identify new sources of raw materials. Since the company was founded, AFYREN's R&D teams, made up of chemists and biologists, have carried out tests on more than 300 potential raw materials made available by the players and partners in the agri-food and farming industries around the world. These tests have enabled AFYREN to qualify 60 families of biomass (agricultural by-products, by-products of the food industry, etc.) that can be transformed into 100% bio-based molecules on an industrial scale. The recent partnership signed with SUEZ even paves the way for the recovery of household organic waste. This work proves that a wide range of organic raw materials can be upcycled in this way, even though they were originally considered to be of little use. This work, carried out on samples from all over the world, is crucial for international development at AFYREN, whose strategy is based on short supply chains with regional sourcing. Innovation fully dedicated to the development of new circular value chains: AFYREN's innovation approach is based on three strategic pillars. Each project must aim to improve processes, support international expansion by exploring new biomass families, or contribute to the development of innovative products and derivatives. For this work, partnerships are often the preferred option. Within this framework, R&D is working in particular on perfecting processes to optimize yields and make AFYREN's industrial solution more competitive. Working closely with the business development team, the R&D teams are also trying to expand the company’s portfolio of acids and their derivatives. The acids produced by AFYREN are platform molecules which, thanks to additional green chemistry steps (esterification, hydrogenation, etc.) can be transformed into derivatives and new products. AFYREN's innovation portfolio currently comprises around ten projects aimed at developing partnerships for new products and circular value chains. It follows an eco-design rationale, incorporating corporate social responsibility (CSR) performance criteria such as carbon footprint, energy mix or the nature of raw materials and their transport.
New Risk • May 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 9.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings are forecast to decline by an average of 9.9% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€11m net loss in 3 years). Revenue is less than US$5m (€3.4m revenue, or US$3.6m). Market cap is less than US$100m (€70.5m market cap, or US$75.9m).
Major Estimate Revision • Apr 09Consensus revenue estimates decrease by 14%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €4.07m to €3.50m. EPS estimate increased from -€0.723 to -€0.44 per share. Chemicals industry in France expected to see average net income growth of 20% next year. Consensus price target down from €6.30 to €5.75. Share price rose 2.9% to €1.96 over the past week.
Reported Earnings • Apr 03Full year 2023 earnings released: €0.37 loss per share (vs €0.36 loss in FY 2022)Full year 2023 results: €0.37 loss per share (further deteriorated from €0.36 loss in FY 2022). Net loss: €9.59m (loss widened 4.2% from FY 2022). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in France.
New Risk • Jan 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 41% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€5.6m net loss in 3 years). Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (41% increase in shares outstanding). Revenue is less than US$5m (€3.6m revenue, or US$4.0m). Market cap is less than US$100m (€73.4m market cap, or US$79.8m).
공시 • Jan 09+ 2 more updatesAFYREN SAS to Report Fiscal Year 2023 Results on Apr 02, 2024AFYREN SAS announced that they will report fiscal year 2023 results on Apr 02, 2024
New Risk • Dec 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€4.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.7m free cash flow). Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Revenue is less than US$5m (€3.6m revenue, or US$4.0m). Market cap is less than US$100m (€53.3m market cap, or US$58.1m).
Price Target Changed • Dec 15Price target decreased by 18% to €7.17Down from €8.77, the current price target is an average from 3 analysts. New target price is 248% above last closing price of €2.06. Stock is down 67% over the past year. The company is forecast to post a net loss per share of €0.43 next year compared to a net loss per share of €0.36 last year.
New Risk • Oct 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €94.2m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€17m net loss in 2 years). Revenue is less than US$5m (€3.6m revenue, or US$3.9m). Market cap is less than US$100m (€94.2m market cap, or US$99.5m).
Major Estimate Revision • Sep 26Consensus revenue estimates increase by 14%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from €3.43m to €3.90m. Forecast losses expected to reduce from -€0.53 to -€0.435 per share. Chemicals industry in France expected to see average net income growth of 1.4% next year. Consensus price target broadly unchanged at €8.60. Share price fell 5.2% to €4.74 over the past week.
Reported Earnings • Sep 20First half 2023 earnings released: €0.20 loss per share (vs €0.16 loss in 1H 2022)First half 2023 results: €0.20 loss per share (further deteriorated from €0.16 loss in 1H 2022). Net loss: €5.12m (loss widened 23% from 1H 2022). Revenue is forecast to grow 87% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in France.
Price Target Changed • Sep 20Price target decreased by 7.5% to €8.60Down from €9.30, the current price target is an average from 3 analysts. New target price is 74% above last closing price of €4.93. Stock is down 30% over the past year. The company is forecast to post a net loss per share of €0.43 next year compared to a net loss per share of €0.36 last year.
New Risk • Jul 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€3.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.8m free cash flow). Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€16m net loss in 3 years). Share price has been volatile over the past 3 months (6.6% average weekly change). Revenue is less than US$5m (€3.5m revenue, or US$3.8m).
Major Estimate Revision • Mar 29Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€0.363 to -€0.417 per share. Revenue forecast of €3.80m unchanged since last update. Chemicals industry in France expected to see average net income decline 0.5% next year. Consensus price target down from €9.30 to €8.77. Share price fell 3.7% to €4.71 over the past week.
Reported Earnings • Mar 22Third quarter 2022 earnings released: €0.099 loss per share (vs €0.048 loss in 3Q 2021)Third quarter 2022 results: €0.099 loss per share (further deteriorated from €0.048 loss in 3Q 2021). Net loss: €2.52m (loss widened 144% from 3Q 2021). Revenue is forecast to grow 57% p.a. on average during the next 4 years, compared to a 4.0% growth forecast for the Chemicals industry in France.
공시 • Jan 10AFYREN Announces Appointment to Its Management TeamAFYREN announced the appointment of three new members to its management team as well as new hires to support its development in France and abroad and to step up its R&D activities. Three strategic appointments Ursula Feulner - Director for Industrial Project Management:- Ursula joins AFYREN's operations team and will lead the upstream phases of industrial projects, including the construction of new plants. AFYREN benefits from her long experience with the SUEZ Group, where she had various roles closely related to the management of industrial projects in Europe, North America, the Middle East and Asia, and worked in risk management for a number of strategic projects. Lea Bassegoda - Human Resources Director:- Lea joins AFYREN to supervise the expansion of its teams. After several years in France and the United States with LVMH and then Danone, she will use her skills and solid experience to build a global Human Resources policy within the group and to structure the organization in line with the company's culture and strong values. Christophe Dardel - Strategic Partnerships Director:- Christophe has come onboard to identify and lay the groundwork for future international factory projects and related strategic partnerships. He has long and solid international experience acquired at several companies, and in particular with Royal DSM for more than 15 years. As a former member of the Executive Committee, Christophe was in charge of the development of the DSM Dyneema unit, which experienced strong organic growth through the establishment of several factories and key partnerships around the world.
공시 • Dec 14+ 2 more updatesAFYREN SAS to Report First Half, 2023 Results on Oct 02, 2023AFYREN SAS announced that they will report first half, 2023 results on Oct 02, 2023
Price Target Changed • Nov 16Price target decreased to €9.30Down from €10.70, the current price target is an average from 3 analysts. New target price is 89% above last closing price of €4.93. Stock is down 46% over the past year.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Patrizia Marraghini was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 28First half 2022 earnings released: EPS: €0 (vs €0.44 loss in 1H 2021)First half 2022 results: EPS: €0. Net loss: €4.16m (loss widened 170% from 1H 2021). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Chemicals industry in France.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Chairman of the Board Stefan Borgas was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Chairman of the Board Stefan Borgas was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.